Archive · 21 Aug 2026
Mankind Pharma Signs China Deal for Two Insulin Products
Mankind Pharma has made a deal with a Chinese company to sell two insulin treatments in India.
The treatments are Insulin Degludec and a combination of Insulin Degludec and Insulin Aspart.
Both medicines are injectable treatments for diabetes care.
Insulin Degludec works for a long time, while Insulin Aspart works more quickly.
The deal gives Indian patients more diabetes-treatment options.
It is part of Mankind Pharma’s plan to bring medicines from other countries to India.
The company says its large network can help distribute the products.
Mankind Pharma also wants to grow its business in long-term treatments such as diabetes care.
Mankind Pharma signed an exclusive India licensing and marketing agreement with China-based Chongqing Chenan Biopharmaceutical.
The deal covers Insulin Degludec and a combination of Insulin Degludec and Insulin Aspart.
Mankind Pharma will commercialise both injectable treatments in India.
The agreement expands the company’s injectable diabetes portfolio and chronic-therapy presence.
Mankind Pharma has more than 18,500 field professionals, 32 manufacturing facilities and seven research centres in India.
- Who
- Mankind Pharma and China-based Chongqing Chenan Biopharmaceutical.
- What
- An exclusive India in-licensing and marketing agreement for two injectable insulin products.
- When
- The agreement was announced on Thursday; the exact date was not specified.
- Where
- India, with Chongqing Chenan Biopharmaceutical based in China.
- Why
- To expand Mankind Pharma’s injectable diabetes portfolio, increase its chronic-therapy presence and offer Indian patients additional treatment options.
- Products
- Insulin Degludec and a combination of Insulin Degludec and Insulin Aspart
- Market
- India
- Agreement
- Exclusive in-licensing and marketing agreement
- Field force
- More than 18,500 professionals
- Doctor reach
- More than five lakh doctors across urban and rural areas
- Manufacturing
- 32 manufacturing facilities in India
- Research and development
- Seven centres supported by more than 740 scientists
